Liege, Belgium, 21 September 2021 -17:50 CEST - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces an update on its Research & Development strategy regarding the PeriNesta® product candidate.

At inception, the PeriNesta® product candidate was intended to specifically target relief of hot flushes, and/or vasomotor symptoms (VMS), while providing effective contraception for women who are starting to exit the reproductive stage and are transitioning into postmenopause, a period called perimenopause. To do so, Mithra intended to conduct a safety study with a comparable formulation to E4 15 mg/DRSP 3 mg in women aged around 50 years of age affected by VMS.

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 16:01:11 UTC.